Nyxoah (NASDAQ:NYXH - Free Report) had its target price lowered by Stifel Nicolaus from $15.00 to $14.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.
Separately, HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Nyxoah in a report on Tuesday, April 8th.
View Our Latest Research Report on NYXH
Nyxoah Trading Down 0.2 %
NASDAQ:NYXH traded down $0.02 on Monday, reaching $6.02. 35,009 shares of the company's stock were exchanged, compared to its average volume of 65,829. The firm has a market capitalization of $204.87 million, a price-to-earnings ratio of -3.22 and a beta of 1.55. Nyxoah has a 52-week low of $5.55 and a 52-week high of $12.21. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. The business has a fifty day moving average of $8.58 and a 200-day moving average of $9.00.
Nyxoah (NASDAQ:NYXH - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.03). The business had revenue of $1.35 million for the quarter, compared to analysts' expectations of $2.02 million. Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. As a group, analysts expect that Nyxoah will post -1.91 earnings per share for the current year.
Hedge Funds Weigh In On Nyxoah
A number of institutional investors and hedge funds have recently modified their holdings of NYXH. Vestal Point Capital LP acquired a new position in shares of Nyxoah during the 4th quarter worth about $23,394,000. Ameriprise Financial Inc. purchased a new stake in Nyxoah during the fourth quarter worth approximately $135,000. Walleye Capital LLC boosted its holdings in Nyxoah by 23.9% in the fourth quarter. Walleye Capital LLC now owns 14,831 shares of the company's stock valued at $119,000 after purchasing an additional 2,862 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Nyxoah in the fourth quarter valued at approximately $187,000. Finally, Geode Capital Management LLC raised its holdings in Nyxoah by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock worth $137,000 after purchasing an additional 2,774 shares in the last quarter.
About Nyxoah
(
Get Free Report)
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Featured Articles
Before you consider Nyxoah, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nyxoah wasn't on the list.
While Nyxoah currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
